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treated with PIO 30 mg/MF rather than SU/MF, one
death was avoided (after 15 years of treatment). PIO was
more expensive, but this was in part offset by a reduction
in complications. The average undiscounted patient life-
time additional cost of treatment with PIO combinations
over their alternatives ranges from 9421 Denmark Kroner
(DKK) to a maximum of 74,687DKK. The incremental cost
per life year gained of PIO 30 mg/MF relative to SU/MF,
and RSG 8 mg/MF is 208,657DKK and 167,060DKK,
respectively.
CONCLUSION: This model suggests that combined
treatments with pioglitazone improve survival and reduce
complications in patients with type 2 diabetes and repre-
sents a cost-effective use of scarce resources when judged
against other therapeutic interventions. It is necessary to
confirm the results of this theoretical model once long-
term effectiveness data with the compared alternatives
are available.
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OBJECTIVES: The treatment of diabetic foot ulcers is
extremely costly and such ulcers have potentially pro-
found consequences for the patient. Apligraf, a living hu-
man skin equivalent, has been shown in clinical trials to
be effective in the management of DFUs resistant to stan-
dard care. However, such trials provide little or no infor-
mation about long-term costs. We attempt to estimate the
costs of treatment in the Netherlands with standard care
and the cost-effectiveness of Apligraf.
METHODS: A Markov chain model was developed to
compare the treatment costs of standard care (good
wound care) with Apligraf for treatment of diabetic foot
ulcers. The states in the model relate to the condition of
the ulcer and the amputation status of the patient. Tran-
sition probabilities were calculated using data from the
Apligraf DFU pivotal study and other published litera-
ture. Cost data were drawn from a number of sources in
the Netherlands.
RESULTS: The monthly cost of treating an uninfected ul-
cer is 432 Euros, while treating an infected or gangrenous
ulcer costs 1963 and 2359 Euros per month, respectively.
Amputation costs range from 7582 Euros (toe) to 15,810
Euros (whole foot). For patients receiving good wound
care, the annual cost of care is 4775 Euros. The results
suggest that costs incurred in using Apligraf are recov-
ered within about a year of initiating treatment. Patients
receiving Apligraf experience improved healing rates and
fewer amputations. As a result, Apligraf was more cost-
effective than good wound care.
CONCLUSION: Apligraf promises to be a cost-effective
treatment for patients with DFU resistant to normal care.
More rapid healing and reduced number of amputations
mean that patients will have a better quality of life. Fur-
ther studies are needed to examine the long-term costs
and effects of Apligraf.
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OBJECTIVES: Treatment costs for type 2 diabetic pa-
tients in Germany amount to more than 31 billion DM
per year, mainly because of related complications. In ac-
cordance with the St. Vincent declaration, these compli-
cations should be reduced at least by one third by treat-
ing according to current guidelines.
METHODS: The CODE-2 study results described the ac-
tual treatment of diabetic patients and associated costs. This
analysis focuses on those 47% of diabetic patients who had
no complications, with the aim of preventing long-term
complications in these patients. The European Diabetes Pol-
icy Group guidelines were applied to define the optimal
therapy regarding blood glucose, lipids and blood pressure.
Costs of guideline-related medication (antidiabetic, lipid
lowering agents and antihypertensive drugs) and costs of ad-
ditional outpatient treatment were calculated using official
tariffs. These results were compared to the cost of current
treatment as assessed in CODE-2.
RESULTS: Guideline treatment would induce 1270 DM
cost per patient for additional medication and outpatient
treatment. For office-based physicians who treat nearly
10% of their patients for diabetes, that would mean a
budget increase of nearly 90,000 DM per year for each
physician. Thus, for all of Germany annually about 2.1
billion DM would have to be invested in diabetes patients
who do not have complications.
CONCLUSIONS: Treatment of patients with type 2 dia-
betes according to the guidelines makes a huge invest-
ment necessary. Nevertheless, this could be balanced by
avoiding long-term complications in the future. Assum-
ing optimal treatment according to guidelines could pre-
vent one third of late diabetes-related complications and
by using the published data of the CODE-2 study, poten-
tial cost savings of 2.9 billion DM could be achieved,
which actually exceeds the cost of prevention.
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